The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tarlatamab-induced immune-related adverse events: Retrospective real-world pharmacovigilance study using FAERS database.
 
Nikhil Vojjala
No Relationships to Disclose
 
Jayalekshmi Jayakumar
No Relationships to Disclose
 
Charmi Bhanushali
No Relationships to Disclose
 
Rishab Prabhu
No Relationships to Disclose
 
Akshit Chitkara
No Relationships to Disclose
 
Jasmeet Kaur
No Relationships to Disclose
 
Moazzam Shahzad
No Relationships to Disclose
 
Ibrahim Azar
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Genmab
Other Relationship - techspert.io
 
Forat Lutfi
No Relationships to Disclose
 
Zahra Mahmoudjafari
Leadership - Hematology Oncology Pharmacists Association
Honoraria - Bristol Myers Squibb Foundation; Genentech; Kite/Gilead; Pfizer; Sanofi
 
Muhammad Atif Khan
No Relationships to Disclose
 
Joseph McGuirk
Employment - University of Kansas Health System
Leadership - University of Kansas Cancer Center
Honoraria - AlloVir; Autolus; Bristol-Myers Squibb/Sanofi; CARGO Therapeutics; crispr therapeutics; Kite, a Gilead company; Legend Biotech; Nektar; Novartis; Sana Biotechnology
Consulting or Advisory Role - Allovir; crispr therapeutics; EcoR1 Capital; Fosun Kite Biotechnology Co., Ltd.; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics; Nektar; Novartis; Sana Biotechnology, Inc.; Sanofi US Services, Inc.
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company; SITC/ACCC; Syncopation Life Sciences
 
Prakash Neupane
Research Funding - Merck Sharp & Dohme
 
Nausheen Ahmed
Consulting or Advisory Role - BMS; Invivyd; Kite/ Gilead; Legend Biotech
Research Funding - Kite/Gilead (Inst)